Target intelligence / Profile preview

cAMP-dependent protein kinase (Protein Kinase A) (PKA)

Target
PKA
Molecular classification
Enzyme, Serine/threonine protein kinase
01

Overview

cAMP-dependent protein kinase (PKA) is a ubiquitous serine/threonine kinase that serves as the primary effector of the second messenger cyclic AMP (cAMP) in eukaryotic cells (StatPearls, 2023). The enzyme typically exists as a heterotetrameric holoenzyme composed of two regulatory subunits and two catalytic subunits; upon the binding of cAMP to the regulatory subunits, the catalytic subunits dissociate and become active (UniProt, 2024). These active subunits subsequently phosphorylate a wide array of cytoplasmic and nuclear targets, such as the cAMP-response element-binding (CREB) protein, thereby regulating diverse physiological processes including metabolism, cell growth, and synaptic plasticity (PubMed: 10648231). Dysregulation of PKA signaling is implicated in various pathologies, including Carney complex, Cushing's syndrome, and several types of cancer (NIH, 2022). Because PKA is involved in many essential cellular functions, therapeutic strategies often focus on indirect modulation via G protein-coupled receptors or phosphodiesterases to achieve tissue-specific effects and minimize systemic toxicity (PubMed: 28814723).

Other names
Protein Kinase AAdenosine 3',5'-monophosphate-dependent protein kinasePKA signaling pathwaycAMP-PKA pathway
02

Mechanism of action

PKA is activated by the binding of cAMP to its regulatory subunits, which induces a conformational change that releases active catalytic subunits to phosphorylate serine and threonine residues on specific substrate proteins (StatPearls, 2023).

03

Biological functions

Signal transductionMetabolismCell cycleApoptosisGene expressionCell proliferation
04

Disease associations

CancerEndocrine disorderCardiovascular diseaseNeurodegenerative diseaseInflammation
05

Safety considerations

Pleiotropic effects due to ubiquitous expressionCardiovascular toxicity including arrhythmiasMetabolic disturbances such as altered glucose homeostasisPotential for oncogenesis or tumor suppression depending on tissue context
06

Interacting drugs

Forskolin

5 more in the full profile.

07

Biomarkers

cAMP levelsPhospho-CREB (pCREB)PRKAR1A expression levelsPRKACA mutation status

Beyond the preview

Go deeper on cAMP-dependent protein kinase (Protein Kinase A) (PKA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cAMP-dependent protein kinase (Protein Kinase A) (PKA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call